BridgeBio Pharma, Inc. has announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C (ON) state. BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity. BBO-8520 drives substantial tumor growth inhibition in multiple preclinical models, even after emergence of resistance to sotorasib, an FDA approved (OFF) state inhibitor of KRASG 12C.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.26 USD | +1.02% |
|
-0.36% | -37.48% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.48% | 4.68B | |
+4.57% | 96.72B | |
+5.66% | 41.43B | |
-12.84% | 32.7B | |
+80.99% | 29.06B | |
-15.58% | 15.38B | |
-9.56% | 12.97B | |
-12.22% | 11.36B | |
+183.25% | 9.9B | |
+3.60% | 8.93B |
- Stock Market
- Equities
- BBIO Stock
- News BridgeBio Pharma, Inc.
- BridgeBio Pharma, Inc. Announces FDA Clearance of IND Application for BBO-8520